An updated meta-analysis of XRCC4 rs1805377 polymorphism and the risk of cancer based on 23 case-control studies

CURRENT STATUS: POSTED

Xin-yuan Zhang  
China Medical University

Xiao-han Wei  
China Medical University

Bao-jie Wang  
China Medical University

Jun Yao  
yaojun198717@163.com  
China Medical University  
Corresponding Author  
ORCiD: 0000-0003-0781-5694

DOI:  
10.21203/rs.2.16037/v1

SUBJECT AREAS  
Medical Genetics

KEYWORDS  
XRCC4, Cancer, polymorphism, meta-analysis
Abstract

Background The growing studies reports that the genes participating in repairing of DNA double-strand breaks may be cancer-susceptibility genes. Rs1805377 (A>G) is a functional single nucleotide polymorphism (SNP) in the x-ray cross-complementing group 4 (XRCC4) gene that may be involved in the etiology of cancer. However, no conclusive results can be determined from individually published studies. Thus, we performed a meta-analysis to examine the association between XRCC4 rs1805377 polymorphism and cancer risk.

Methods The potential literatures were searched using three online electronic databases (PubMed, Embase, and Web of Science). The available studies were included according to the inclusion criteria. The pooled analysis were performed to explore the association between XRCC4 rs1805377 locus and the risk of cancer. Additionally, we also performed subgroup analysis and sensitivity analysis.

Results Twenty-three studies were included in our meta-analysis. It contained 9,433 cancer patients and 10,337 healthy controls. The pooled results showed that there was no association between rs1805377 and the risk of cancer. Under the dominant model, the final pooled odds ratios (ORs) was 1.115 (95% confidence intervals: 0.956-1.301; P = 0.165) in a random effects model without the statistical significance. The subgroup analysis by ethnicity and source of controls also didn’t find that rs1805377 polymorphism was related to cancer occurrence. In the subgroup by type of cancers, the significant association was only found in gastric antrum adenocarcinoma.

Conclusions our meta-analysis suggested that there was no association between rs1805377 polymorphism and cancer occurrence. It may provide useful information for the relevant studies on the etiology of cancer in future.

Background
Presently, cancer remains one of the leading cause of mortality globally because of an aging population, the prevalence of smoking, a lack of physical inactivity, and other lifestyle factors. It is a cellular abnormality that is initiated by uncontrolled growth caused by an accumulation of damage or mutation in the genetically mediated factors and environmental factors, which causes cells to evade the signal mediated controls of cell growth and death. The genetic factor has a greater effect on cancer initiation than the environmental and lifestyle factors. Presently, a number of potential susceptible genes and variations have been examined and identified to participate in cancer occurrence. For DNA damage repair, the usually known molecular pathways includes sing-strand damage repair, double-strand break repair, and damage reversal. Presently, the evidence finds that the genes participating in repairing of DNA double-strand breaks may be involved in modifying the risk of various cancers. Among them, the gene x-ray cross-complementing group 4 (XRCC4), which is a specific member of nonhomologous end-joining system, functions together with DNA ligase IV and the DNA-dependent protein kinase in the repair of DNA double-strand breaks. This protein exerts its function in both non-homologous end joining and the completion of V(D)J recombination. XRCC4 gene is located on the chromosome 5q14.2 with the full length 276 kb and contains 23 exons. Mutations in XRCC4 gene can cause severe short stature, gonadal failure, microcephaly, and increased genomic instability. Additionally, its mutations also cause primordial dwarfism without causing immunodeficiency. XRCC4 knockdown by lentivirus-mediated shRNA had no significant effect on proliferation of triple-negative breast cancer (TNBC) cells while knockdown of XRCC4 could substantially increase the sensitivity of TNBC cells to ionizing radiation. Moreover, XRCC4 expression might have an influence on results of
radiotherapy for patients with esophageal squamous cell carcinoma. Another study suggests that XRCC4 may be an independent prognostic factor for hepatocarcinoma patients, and that decreasing XRCC4 expression may be beneficial for post-operative adjuvant transarterial chemoembolization treatment in hepatocarcinoma.

The variation of XRCC4 gene can be involved in the etiology of cancer by influencing the normality of the protein function. Rs1805377 (A>G) is in intron 7, with the potential function of abolishing an acceptor splice site at exon 8. This polymorphic locus has been reported to be related with the occurrence of different cancers and tumor diffusing capacity. However, their results remain inconclusive due to insufficient population size, genetic heterogeneity of samples, and other possible confounding bias.

Meta-analysis is a powerful method for quantitatively summarizing the results of different studies. An advantage is increasing the sample size by pooling the relevant studies, which can, to some degree, decrease the occurrence of a false-positive or false-negative association generated by random error. Previous meta-analysis studies have investigated the association between XRCC4 gene polymorphisms and the risk of cancer, but as research progressed, an exhaustive and updated meta-analysis is needed to be conducted. Consequently, in our present study, we carried out a meta-analysis of studies examining the association between XRCC4 gene polymorphism and the risk of cancer.

Methods

2.1. Literature search and eligibility of relevant studies

To identify studies eligible for our meta-analysis, three online electronic databases (PubMed, Embase, and Web of Science) were searched (the last update date was February 2019). The following key words were used in the literature search: XRCC4, rs1805377, and cancer. The additional potential studies were also screened from the included articles and
relevant reviews.

Studies which were included in this meta-analysis met the following inclusion criteria: (1) case-control studies; (2) patients with cancer; (3) available allele or genotype frequencies; (4) of the studies with the same or overlapping data published by the same authors, the most latest ones were selected. Major reasons for exclusion of studies were: (1) without controls; (2) duplicate of earlier publication; (3) no usable genotype frequency data.

2.2. Data extraction

According to the inclusion criteria listed above, two of the authors extracted information from all eligible publications independently. Any disagreement was resolved through discussion until the two authors reached a consensus. We calculated the number of genotypes based on the allele frequencies according to Hardy-Weinberg equilibrium formula. The following data were included from each study: the first author’s last name, publication year, region, ethnicity, type of cancer, source of controls, and numbers of genotype between cases and controls.

2.3. Statistical analysis

Hardy-Weinberg equilibrium was checked in control groups using chi-square goodness-of-fit or exact test before statistical analysis (significant at the 0.05 level). The strength of the association between XRCC4 rs1805377 locus and cancer risk was measured by ratios (ORs) and 95% confidence intervals (CIs). Pooled effect sizes across studies were performed by a random effects model (DerSimonian and Laird method), which evaluates the likely effect size across different populations and takes heterogeneity across studies into account.

The pooled ORs were calculated using the allele comparison model, dominant comparison model, and recessive comparison model, which were reported previously. Then the
most appropriate genetic model was selected in our pooled analysis to according to the criteria. The degree of heterogeneity between studies was measured by Q-statistic. P value >0.05 for the Q-test indicated a lack of heterogeneity and P value <0.05 indicated an existence of heterogeneity. The $I^2$ is the proportion of observed variance in effect sizes attributable to the true differences among studies. A conventional interpretation of $I^2$ is that it defines bounds for low (<25%), moderate (50%), and high (>75%) heterogeneity. Subgroup analysis was performed by ethnicity, source of controls, and types of cancer. Sensitivity analysis was carried out to assess the potential influences of any single study on the pooled effect size. It was performed by omitting each included study to assess the stability of the results.

An estimate of publication bias was performed by visual inspection of a funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). An asymmetric plot indicated a possible publication bias, and the degree of asymmetry was tested using Egger’s test (P <0.05 was considered to indicate significant publication bias).

All statistical tests were two-sided. The meta-analysis was performed using Stata version 10.0 (Stata Corp., College Station, TX, USA).

Results

There were 23 eligible studies as a result of the searching and screening carried out on the basis of our eligibility criteria. Subjects involved in these studies are not overlapping. We collected 23 case-control studies, which contained 9,433 patients with cancer (i.e., cases) and 10,337 unaffected participants (i.e., controls). The individuals with the different genetic backgrounds and different types of cancer were included (e.g., East
Asian and Caucasian; breast cancer, bladder cancer, renal cell carcinoma, oral cancer, glioma, thyroid cancer, non-small-cell lung cancer, prostate cancer, gastric antrum adenocarcinoma, non-hodgkin lymphoma, pancreatic cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma). The main characteristics of the included studies were listed in Table 1. The genotype and allele frequencies of rs1805377 SNP and HWE in controls were showed in Table 2. Of the 23 studies, there were four publications deviated significantly from HWE \(^{31,38,40,47}\).

3.1 meta-analysis result

The association between rs1805377 polymorphism and the risk of different cancers was evaluated using the pooled ORs and corresponding 95% CIs under the following genetic models: homozygous codominant, heterozygous codominant, dominant, recessive, and allele contrast (Table 3 and Figure 1). Finally, the dominant model was selected to perform the pooled analysis according to the selection criteria of genetic models. The pooled results showed that no association was observed between rs1805377 polymorphism and the risk of cancer. In the dominant model, the summary OR generated by a random effects model was 1.115 (95% CI, 0.956–1.301; \( P = 0.165 \)). Results of subgroup analysis by ethnicity showed that the SNP was not associated with the risk of cancer among East Asian and Caucasian (Table 4). Moreover, there was no association between rs1805377 and cancer in subgroup analysis in light of the source of controls (hospital based and population-based). Additionally, we also performed the subgroup analysis by the type of cancer. The results showed that rs1805377 increased the occurrence of gastric antrum adenocarcinoma, but not other cancer types (Table 4).

3.2 Sensitivity analysis

Sensitivity analysis was carried out by removing each included study to assess the influence of every single study. The corresponding pooled ORs were no significant change.
when removing one study at the time from each meta-analysis, indicating that our results were stable and reliable.

3.3 Publication bias

Funnel plot was performed to assess the publication bias of literature. Funnel plot is shown in Figure 2. Egger’s test was used to supply statistical evidence for funnel plot symmetry. The results showed no significant effect of publication bias ($P_e = 0.950$) (Table 3).

Discussion

Our meta-analysis explored the association between XRCC4 rs1805377 polymorphism and cancer risk. A total of 23 case-control studies were included, which contained 9,433 cases and 10,337 controls. The pooled results indicated that there was an association, and subgroup analysis by ethnicity, source of controls, and types of cancer further investigated the distribution deviation between cases and controls. Previously, there were three meta-analyses reported the putative association between rs1805377 and cancer risk $^{18-20}$. Although our meta-analysis seems redundant, there are still some highlights in our present analysis. On the one hand, the newly published studies were included after the previous meta-analyses. A total of 23 studies were included to comprehensively investigate the role of rs1805377 in the occurrence of cancer. It contained various types of cancer (breast cancer, bladder cancer, renal cell carcinoma, oral cancer, glioma, thyroid cancer, non-small-cell lung cancer, prostate cancer, gastric antrum adenocarcinoma, non-hodgkin lymphoma, pancreatic cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma). On the other hand, we performed subgroup analysis by ethnicity, source of controls, and types of cancer to further explore the existing of heterogeneity. Therefore, to some degree, the final results in our meta-
analysis is more accurate and comprehensive than the previous meta-analysis. However, the relatively small sample sizes of some cancers (renal cell carcinoma, non-small-cell lung cancer, gastric antrum adenocarcinoma, non-hodgkin lymphoma, hepatocellular carcinoma, and esophageal squamous cell carcinoma) limited our ability to isolate stable effects for these subgroups. Our meta-analysis found an association between rs1805377 and the risk of gastric antrum adenocarcinoma. Regrettably, the results need to be interpreted cautiously considering that just one study was included. Thus, we cannot obtain the accurate and comprehensive results of the association between rs1805377 and the risk of the above cancers because of the limitation of sample size.

XRCC4 is indispensable for non-homologous end joining, the major pathway for repairing DNA double-strand breaks. Thus, it is generally believed that abnormalities in XRCC4 cause severe combined immunodeficiency. But one patient with the mutations in XRCC4 gene displayed the microcephaly and progressive ataxia but a normal immune response, which suggested that XRCC4 deficiency in human subjects caused a marked neurological phenotype but no overt immunodeficiency. Moreover, the XRCC4 c.482G>A mutation, which affects the last nucleotide of exon 4, induces defective splicing of XRCC4 pre-mRNA mainly resulting in premature protein truncation and most likely loss of XRCC4 function. In addition, genome-wide gene expression analysis revealed age-related impairment of mitosis, telomere and chromosome maintenance and induction of genes associated with DNA repair and non-homologous end-joining, most notably XRCC4 and ligase 4.

Considering the inconsistency of the current results, more effort need to explore the role of XRCC4 mutations in the occurrence of cancer.

Conclusion
Our study found no association between the rs1805377 in *XRCC4* gene and the risk of cancer. The studies containing different types of cancer need to validate the findings of this meta-analysis and to ascertain the epigenetic mechanisms and environmental influences that contribute to the risk of cancer.

**Abbreviations**

*SNP*: single nucleotide polymorphism; *XRCC4*: x-ray cross-complementing group 4; *HWE*: Hardy-Weinberg equilibrium; *ORs*: Odds ratios; *CIs*: confidence interval.

**Declarations**

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

Not applicable

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

Not applicable

**Authors’ contributions**

XYZ and JY conceived and designed the study. XYZ, XHW and BJW were responsible for collection of data, performing statistical analyses, and manuscript preparation. JY were responsible for reviewing the data. All authors contributed to drafting the manuscript, and all read and approved the final version.
Acknowledgements

Not applicable

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. Mar 2015;65(2):87-108.

2. Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. Jun 2015;93:52–79.

3. Zhao L, Gu A, Ji G, Zou P, Zhao P, Lu A. The association between ATM IVS 22–77 T>C and cancer risk: a meta-analysis. PloS one. 2012;7(1):e29479.

4. Reardon JT, Sancar A. Purification and characterization of Escherichia coli and human nucleotide excision repair enzyme systems. Methods in enzymology. 2006;408:189-213.

5. Smolarz B, Michalska MM, Samulak D, Romanowicz H, Wojcik L. Polymorphism of DNA Repair Genes via Homologous Recombination (HR) in Ovarian Cancer. Pathology oncology research: POR. Feb 2 2019.

6. Gerodimos CA, Chang HHY, Watanabe G, Lieber MR. Effects of DNA end configuration on XRCC4-DNA ligase IV and its stimulation of Artemis activity. The Journal of biological chemistry. Aug 25 2017;292(34):13914-13924.

7. de Bruin C, Mericq V, Andrew SF, et al. An XRCC4 splice mutation associated with severe short stature, gonadal failure, and early-onset metabolic syndrome. The Journal of clinical endocrinology and metabolism. May 2015;100(5):E789–798.

8. Rosin N, Elcioglu NH, Beleggia F, et al. Mutations in XRCC4 cause primary microcephaly, short stature and increased genomic instability. Human molecular genetics. Jul 1
9. Saito S, Kurosawa A, Adachi N. Mutations in XRCC4 cause primordial dwarfism without causing immunodeficiency. *Journal of human genetics*. Aug 2016;61(8):679-685.

10. Wen Y, Dai G, Wang L, Fu K, Zuo S. Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells. *Bioscience reports*. Mar 29 2019;39(3).

11. Hori M, Someya M, Matsumoto Y, et al. Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy. *Medical molecular morphology*. Mar 2017;50(1):25-33.

12. Lu J, Wang XZ, Zhang TQ, et al. Prognostic significance of XRCC4 expression in hepatocellular carcinoma. *Oncotarget*. Oct 20 2017;8(50):87955-87970.

13. Jiao K, Qin J, Zhao Y, Zhang H. Genetic effects of XRCC4 and ligase IV genes on human glioma. *Neuroreport*. Sep 28 2016;27(14):1024-1030.

14. Sharma V, Nandan A, Sharma AK, et al. Signature of genetic associations in oral cancer. *Tumour biology: the journal of the International Society for Onco-developmental Biology and Medicine*. Oct 2017;39(10):1010428317725923.

15. Romanowicz H, Pyziak L, Jablonski F, Brys M, Forma E, Smolarz B. Analysis of DNA Repair Genes Polymorphisms in Breast Cancer. *Pathology oncology research: POR*. Jan 2017;23(1):117-123.

16. Saadat M, Saadat S. Susceptibility to Breast Cancer and Intron 3 Ins/Del Genetic Polymorphism of DNA Double-Strand Break Repair Gene XRCC4. *Journal of medical biochemistry*. Oct 2015;34(4):409-413.

17. Chene G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. *American journal of epidemiology*. Sep 15 1996;144(6):610-621.

18. Zhou LP, Luan H, Dong XH, Jin GJ, Ma DL, Shang H. Association of functional
polymorphisms of the XRCC4 gene with the risk of breast cancer: a meta-analysis. *Asian Pacific journal of cancer prevention: APJCP.* 2012;13(7):3431-3436.

19. Shao N, Jiang WY, Qiao D, et al. An updated meta-analysis of XRCC4 polymorphisms and cancer risk based on 31 case-control studies. *Cancer biomarkers: section A of Disease markers.* 2012;12(1):37-47.

20. Liu K, Jiang Y. Polymorphisms in DNA Repair Gene and Susceptibility to Glioma: A Systematic Review and Meta-Analysis Based on 33 Studies with 15 SNPs in 9 Genes. *Cellular and molecular neurobiology.* Mar 2017;37(2):263-274.

21. Munafo MR, Flint J. Meta-analysis of genetic association studies. *Trends in genetics: TIG.* Sep 2004;20(9):439-444.

22. Yang B, Fan S, Zhi X, et al. Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: a meta-analysis from 114 studies with 15411 cases and 21970 controls. *PloS one.* 2014;9(2):e87497.

23. Thakkinstian A, McEllduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. *Statistics in medicine.* May 15 2005;24(9):1291-1306.

24. Xu FL, Wu X, Zhang JJ, Wang BJ, Yao J. A meta-analysis of data associating DRD4 gene polymorphisms with schizophrenia. *Neuropsychiatric disease and treatment.* 2018;14:153-164.

25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Bmj.* Sep 6 2003;327(7414):557-560.

26. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. *Genetic epidemiology.* Feb 2005;28(2):123-137.

27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj.* Sep 13 1997;315(7109):629-634.

28. Fu YP, Yu JC, Cheng TC, et al. Breast cancer risk associated with genotypic
polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. *Cancer research.* May 15 2003;63(10):2440–2446.

29. Garcia-Closas M, Egan KM, Newcomb PA, et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. *Human genetics.* May 2006;119(4):376–388.

30. Figueroa JD, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. *Carcinogenesis.* Aug 2007;28(8):1788–1793.

31. Margulis V, Lin J, Yang H, Wang W, Wood CG, Wu X. Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.* Sep 2008;17(9):2366–2373.

32. Tseng HC, Tsai MH, Chiu CF, et al. Association of XRCC4 codon 247 polymorphism with oral cancer susceptibility in Taiwan. *Anticancer research.* May-Jun 2008;28(3A):1687–1691.

33. Liu Y, Zhou K, Zhang H, et al. Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma. *Human mutation.* Mar 2008;29(3):381–389.

34. Chiu CF, Tsai MH, Tseng HC, et al. A novel single nucleotide polymorphism in XRCC4 gene is associated with oral cancer susceptibility in Taiwanese patients. *Oral oncology.* Sep 2008;44(9):898–902.

35. Siraj AK, Al-Rasheed M, Ibrahim M, et al. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. *Journal of endocrinological investigation.* Oct 2008;31(10):893–899.

36. Tseng RC, Hsieh FJ, Shih CM, Hsu HS, Chen CY, Wang YC. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. *Cancer.* Jul 1 2009;115(13):2939–2948.
37. Luedeke M, Linnert CM, Hofer MD, et al. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. Nov 2009;18(11):3030–3035.

38. Long XD, Ma Y, Huang YZ, et al. Genetic polymorphisms in DNA repair genes XPC, XPD, and XRCC4, and susceptibility to Helicobacter pylori infection-related gastric antrum adenocarcinoma in Guangxi population, China. *Molecular carcinogenesis*. Jun 2010;49(6):611–618.

39. Gomes BC, Silva SN, Azevedo AP, et al. The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk. *Oncology reports*. Oct 2010;24(4):1079–1085.

40. Shen M, Menashe I, Morton LM, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma in a pooled analysis of three studies. *British journal of haematology*. Nov 2010;151(3):239–244.

41. Rajaraman P, Hutchinson A, Wichner S, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. *Neuro-oncology*. Jan 2010;12(1):37–48.

42. Mandal RK, Singh V, Kapoor R, Mittal RD. Do polymorphisms in XRCC4 influence prostate cancer susceptibility in North Indian population? *Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals*. May 2011;16(3):236–242.

43. Mittal RD, Gangwar R, Mandal RK, Srivastava P, Ahirwar DK. Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer. *Molecular biology reports*. Feb 2012;39(2):1667-1675.

44. Zhao P, Zou P, Zhao L, et al. Genetic polymorphisms of DNA double-strand break repair
pathway genes and glioma susceptibility. *BMC cancer*. May 10 2013;13:234.

45. Ding Y, Li LN. Association between single nucleotide polymorphisms of X-ray repair cross-complementing protein 4 gene and development of pancreatic cancer. *Genetics and molecular research: GMR*. Aug 14 2015;14(3):9626–9632.

46. Shen Q, Tian Y, Li K, Jiang Q, Xue H, Yang S. Association of single nucleotide polymorphisms of DNA repair gene and susceptibility to pancreatic cancer. *International journal of clinical and experimental pathology*. 2015;8(3):3180–3185.

47. Su Y, Qi S, Dou C, Shuang L, Yan H. Association of LIG4 and XRCC4 gene polymorphisms with the risk of human glioma in a Chinese population. *International journal of clinical and experimental pathology*. 2015;8(2):2057–2062.

48. Makkoch J, Praianantathavorn K, Sopipong W, Chuaypen N, Tangkijvanich P, Payungporn S. Genetic Variations in XRCC4 (rs1805377) and ATF6 (rs2070150) are not Associated with Hepatocellular Carcinoma in Thai Patients with Hepatitis B Virus Infection. *Asian Pacific journal of cancer prevention: APJCP*. 2016;17(2):591–595.

49. Yang HL, Qiao DD, Li K, et al. Association of genetic polymorphisms in PRKDC and XRCC4 with risk of ESCC in a high-incidence region of North China. *Tumori*. Mar-Apr 2016;102(2):131–134.

50. Guo C, Nakazawa Y, Woodbine L, et al. XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency. *The Journal of allergy and clinical immunology*. Oct 2015;136(4):1007–1017.

51. Kalfalah F, Seggewiss S, Walter R, et al. Structural chromosome abnormalities, increased DNA strand breaks and DNA strand break repair deficiency in dermal fibroblasts from old female human donors. *Aging*. Feb 2015;7(2):110–122.

**Tables**

Table 1. Baseline characteristics of qualified studies in this meta-analysis.
Table 2. Distribution of genotype and allele frequencies of the XRCC4 rs1805377 polymorphism.

| Author          | Year | Region          | Ethnicity | Controls source     | Type                      |
|-----------------|------|-----------------|-----------|---------------------|---------------------------|
| Fu              | 2003 | Taiwan          | Asian     | hospital-based      | breast cancer             |
| García-Closas   | 2006 | USA             | Caucasian | population-based    | breast cancer             |
| Figueroa        | 2007 | Spain           | Caucasian | hospital-based      | bladder cancer            |
| Margulis        | 2008 | USA             | Caucasian | hospital-based      | renal cell carcinoma      |
| Tseng           | 2008 | Taiwan          | Asian     | hospital-based      | oral Cancer               |
| Liu             | 2008 | China           | Asian     | hospital-based      | glioma                    |
| Chiu            | 2008 | Taiwan          | Asian     | hospital-based      | oral Cancer               |
| Siraj           | 2008 | Saudi Arabia    | Asian     | population-based    | papillary thyroid         |
| Tseng           | 2009 | Taiwan          | Asian     | hospital-based      | non-small-cell I          |
| Leudeke         | 2009 | Germany         | Caucasian | hospital-based      | prostate cancer           |
| Long            | 2010 | China           | Asian     | hospital-based      | gastric antrum            |
| Gomes           | 2010 | Portugal        | Caucasian | hospital-based      | thyroid cancer            |
| Shen            | 2010 | USA and Australia | Caucasian | population-based | non-Hodgkin lym            |
| Rajaraman       | 2010 | USA             | Caucasian | hospital-based      | glioma, mening fibroma    |
| Mandal          | 2011 | India           | Asian     | hospital-based      | prostate cancer           |
| Mittal          | 2012 | India           | Asian     | hospital-based      | urothelial bladder cancer|
| Zhao            | 2013 | China           | Asian     | hospital-based      | glioma                    |
| Ding            | 2015 | China           | Asian     | hospital-based      | pancreatic cancer         |
| Shen            | 2015 | China           | Asian     | hospital-based      | pancreatic cancer         |
| Su              | 2015 | China           | Asian     | hospital-based      | glioma                    |
| Jiao            | 2016 | China           | Asian     | hospital-based      | glioma                    |
| Makkoch         | 2016 | Thailand        | Asian     | hospital-based      | hepatocellular squ carcinoma |
| Yang            | 2016 | China           | Asian     | hospital-based      | esophageal squ carcinoma  |

Abbreviation: $P_{HWE}$ represents the $P$ value of Hardy-Weinberg equilibrium test in the genotype distribution of controls.
Table 3. Summarized ORs with 95% CIs for the association of XRCC4 rs1805377 polymorphism with cancer.

| Polymorphism               | Genetic model | n   | Statistical model | OR    | 95% CI       | p_z  | p_h  | p_e  |
|----------------------------|---------------|-----|-------------------|-------|--------------|------|------|------|
| Rs1805377                  |               |     |                   |       |              |      |      |      |
| Allele contrast            | Random        | 23  |                   | 1.064 | 0.943-1.202  | 0.313|      |      |
| Homozygous codominant      | Random        | 23  |                   | 1.202 | 0.943-1.532  | 0.137|      |      |
| Heterozygous               | Random        | 23  |                   | 1.107 | 0.963-1.272  | 0.155|      |      |
| Dominant                   | Random        | 23  |                   | 1.115 | 0.956-1.301  | 0.115|      |      |
| Recessive                  | Random        | 23  |                   | 1.110 | 0.935-1.319  | 0.233|      |      |

Note: n, the number of studies; p_z, P value for association test; p_h, p value for heterogeneity test; p_e, p value for publication bias test.

Table 4. Stratified analysis of the association of XRCC4 polymorphisms with cancer under dominant model.
| Subgroup analysis                          | n  | OR  | 95% CI       | \(p_z\) | \(\chi^2(\%)\) | \(p_h\) |
|-------------------------------------------|----|-----|--------------|--------|----------------|--------|
| Overall                                   | 23 | 1.115 | 0.956-1.301 | 0.165  | 69.5           | <0.0   |
| Ethnicity                                 |    |      |              |        |                |        |
| East Asians                               | 16 | 1.139 | 0.940-1.380 | 0.185  | 77.8           | <0.0   |
| Caucasians                                | 7  | 0.983 | 0.836-1.157 | 0.837  | 0.0            | 0.9    |
| Source of controls                        |    |      |              |        |                |        |
| Hospital-based                            | 20 | 1.125 | 0.943-1.341 | 0.191  | 72.5           | <0.0   |
| Population-based                          | 3  | 0.981 | 0.824-1.169 | 0.832  | 0.0            | 0.7    |
| Type of cancer                            |    |      |              |        |                |        |
| Breast cancer                             | 2  | 0.971 | 0.811-1.164 | 0.752  | 0.0            | 0.6    |
| Bladder cancer                            | 2  | 0.913 | 0.645-1.292 | 0.606  | 0.0            | 0.8    |
| Renal cell carcinoma                      | 1  | 1.053 | 0.473-2.343 | 0.900  | -              | -      |
| Oral cancer                               | 2  | 0.927 | 0.744-1.156 | 0.500  | 0.0            | 1.0    |
| Gioma                                     | 5  | 1.077 | 0.941-1.233 | 0.280  | 0.0            | 0.8    |
| Thyroid cancer                            | 2  | 1.728 | 0.499-5.987 | 0.388  | 0.0            | 0.5    |
| Non-small-cell lung cancer                | 1  | 0.985 | 0.626-1.552 | 0.949  | -              | -      |
| Prostate cancer                           | 2  | 0.944 | 0.646-1.380 | 0.766  | 0.0            | 0.8    |
| Gastric antrum adenocarcinoma             | 1  | 3.401 | 2.564-4.510 | <0.001 | -              | -      |
| Non-hodgkin lymphoma                      | 1  | 1.125 | 0.678-1.866 | 0.648  | -              | -      |
| Pancreatic cancer                         | 2  | 1.140 | 0.903-1.438 | 0.271  | 0.0            | 0.9    |
| Hepatocellular carcinoma                  | 1  | 1.375 | 0.828-2.283 | 0.218  | -              | -      |
| Esophageal squamous cell carcinoma        | 1  | 0.862 | 0.576-1.291 | 0.471  | -              | -      |

Note: \(n\), the number of studies; \(p_z\), \(p\) value for association test; \(p_h\), \(p\) value for heterogeneity test.

Figures
Figure 1

Forest plot of the association between the rs1805377 polymorphism of XRCC4 and cancer in the dominant genetic model (GG + GA vs. AA).
Figure 2

Funnel plot analysis depicting publication bias in the association between the rs1805377 polymorphism of XRCC4 and cancer.

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

PRISMA IPD checklist.docx